RSS

Cosentyx

The FDA’s recent approval of Novartis’ cosentyx for the treatment of adults with active ankylosing spondylitis (AS) and psoriatic arthritis (PsA), will propel the drug to blockbuster status, according to GlobalData analyst, Alexandra Annis more

News

The US Food and Drug Administration (FDA) has approved Novartis’ Cosentyx (secukinumab) for the treatment of adult patients with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA) more

News